Skip to main content Skip to footer
Algernon Health Inc
  • Home
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Medical & Scientific Advisors
  • Alzheimer’s
    • Overview
    • AD Clinics
    • Markets
    • Resources
  • Pipeline
    • Overview
    • NP-251 (Repirinast)
    • AP-188 (DMT)
  • Companies
    • Algernon NeuroScience
  • News & Media
    • News Releases
    • IR Calendar
    • Presentations
    • Videos/Articles
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEDAR
    • Governance
  • Contact

We are currently in the process of updating our web site to reflect the announced plans to change our company name from Algernon Pharmaceuticals to Algernon Health. Please visit again soon as these changes continue to take effect across the entire web site.

News Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • News Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Annual General Meeting
    • Analysts
  • Stock Data
    • CSE:AGN
    • OTCQB:AGNPF
    • XFRA:AGW2
  • SEDAR
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • News Releases
  • IR Calendar
  • Email Alerts
Mar 13, 2020 2:56pm EDT

Algernon Contacts Gates Foundation Regarding Funding for New Coronavirus Treatments

Mar 13, 2020 8:30am EDT

Algernon Announces Filing of U.S. FDA Pre-IND Meeting Request for Ifenprodil Coronavirus Trial, Expanded Access, and Emergency Use

Mar 11, 2020 3:17pm EDT

Algernon Announces Exercise of Warrants and Broker Warrants

Mar 10, 2020 8:46am EDT

Algernon Announces Coronavirus Update Featured on BioPub Hosted by Dr. KSS MD PhD

Mar 09, 2020 8:45am EDT

Algernon Scales up Manufacturing of NP-120 (Ifenprodil) to Prepare for Coronavirus and Acute Lung Injury US Clinical Trials

Mar 06, 2020 2:34pm EST

Algernon Announces Availability of its NP-120 Ifenprodil Drug for Compassionate Use for Coronavirus

Mar 06, 2020 6:09am EST

Algernon Explores the Use of NP-120 (Ifenprodil) as a Novel Treatment for Coronavirus

Feb 26, 2020 6:00am EST

Algernon Pharmaceuticals to be Featured on BioPub Webcast Hosted by Dr. KSS MD PhD

Feb 21, 2020 6:00am EST

Algernon Pharmaceuticals Announces Increase and Closing of CDN$1.55M Private Placement

Feb 13, 2020 9:00am EST

Algernon Pharmaceuticals Announces Private Placement

  • Previous Pagearrow_back
  • Page 1…
  • …
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Page 20
  • Page 21
  • Page 22
  • Page 23
  • Next Pagearrow_forward
rss_feed News RSS
  • Visit us on Facebook

    Facebook

  • Visit us on Twitter

    Twitter

  • Visit us on LinkedIn

    LinkedIn

  • Email Alerts
  • Email Alerts
  • Contacts
  • RSS News Feed
©2026 Algernon Health Inc. All Rights Reserved.
Privacy Policy Sitemap